Tong Ren Tang Technologies Co. Ltd. (TGRNF)
USD 0.69
(0.0%)
USD 0.69
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 1.3 Billion CNY | -0.58% |
| 2022 | 1.52 Billion CNY | 12.04% |
| 2021 | 1.35 Billion CNY | 5.31% |
| 2020 | 1.26 Billion CNY | 12.15% |
| 2019 | 1.12 Billion CNY | -13.05% |
| 2018 | 1.31 Billion CNY | 3.39% |
| 2017 | 1.27 Billion CNY | 14.19% |
| 2016 | 1.11 Billion CNY | 14.29% |
| 2015 | 977.38 Million CNY | 21.24% |
| 2014 | 804.73 Million CNY | 23.3% |
| 2013 | 652.64 Million CNY | 22.58% |
| 2012 | 531.74 Million CNY | 34.06% |
| 2011 | 381.32 Million CNY | 27.96% |
| 2010 | 310.35 Million CNY | 15.79% |
| 2009 | 268.03 Million CNY | 34.77% |
| 2008 | 246.01 Million CNY | 7.95% |
| 2007 | 184.23 Million CNY | 6.28% |
| 2006 | 173.34 Million CNY | -32.9% |
| 2005 | 256.61 Million CNY | 12.81% |
| 2004 | 230.03 Million CNY | 20.15% |
| 2003 | 190.59 Million CNY | 31.54% |
| 2002 | 144.89 Million CNY | 69.81% |
| 2001 | 85.32 Million CNY | 25.87% |
| 2000 | 67.79 Million CNY | 12.73% |
| 1999 | 60.13 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 107.57 Million USD | 0.0% |
| 2023 FY | - CNY | -0.58% |
| 2023 Q2 | 112.1 Million USD | 0.0% |
| 2023 Q4 | 85.08 Million USD | 0.0% |
| 2022 Q4 | 112.47 Million USD | 0.0% |
| 2022 Q2 | 106.18 Million USD | 0.0% |
| 2022 FY | - CNY | 12.04% |
| 2021 Q2 | 109.75 Million USD | 0.0% |
| 2021 FY | - CNY | 5.31% |
| 2021 Q4 | 95.47 Million USD | 0.0% |
| 2020 FY | - CNY | 12.15% |
| 2020 Q4 | 91.38 Million USD | 0.0% |
| 2020 Q2 | 84.02 Million USD | 0.0% |
| 2019 Q2 | 111.69 Million USD | 0.0% |
| 2019 FY | - CNY | -13.05% |
| 2019 Q4 | 46.44 Million USD | 0.0% |
| 2018 FY | - CNY | 3.39% |
| 2017 FY | - CNY | 14.19% |
| 2016 FY | - CNY | 14.29% |
| 2015 FY | - CNY | 21.24% |
| 2014 FY | - CNY | 23.3% |
| 2013 FY | - CNY | 22.58% |
| 2012 FY | - CNY | 34.06% |
| 2011 FY | - CNY | 27.96% |
| 2010 FY | - CNY | 15.79% |
| 2009 FY | - CNY | 34.77% |
| 2008 FY | - CNY | 7.95% |
| 2007 FY | - CNY | 6.28% |
| 2006 FY | - CNY | -32.9% |
| 2005 FY | - CNY | 12.81% |
| 2004 FY | - CNY | 20.15% |
| 2003 FY | - CNY | 31.54% |
| 2002 FY | - CNY | 69.81% |
| 2001 FY | - CNY | 25.87% |
| 2000 FY | - CNY | 12.73% |
| 1999 FY | - CNY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| AstraZeneca PLC | 13.28 Billion USD | 90.2% |
| Bristol-Myers Squibb Company PFD CONV 2 | 19.41 Billion USD | 93.293% |
| CSPC Pharmaceutical Group Limited | 1.14 Billion USD | -13.437% |
| Clarus Therapeutics Holdings, Inc. | -39.7 Million USD | 3380.008% |
| Novartis AG | 19.51 Billion USD | 93.328% |
| PT Kalbe Farma Tbk. | 288.13 Million USD | -351.987% |